Karlsson, William Kristian
Ashina, Håkan
Cullum, Christopher Kjær
Christensen, Rune Häckert
Al-Khazali, Haidar Muhsen
Amin, Faisal Mohammad
Ashina, Messoud
Iljazi, Afrim
Thomsen, Andreas Vinther
Chaudhry, Basit Ali
Tesfay, Betel
Thuraiaiyah, Janu
Kokoti, Lili
Rasmussen, Nadja Bredo
Domínguez-Moreno, Rogelio
Do, Thien Phu
Zhuang, Zixuan Alice
,
Funding for this research was provided by:
Novartis Pharma AG
Lundbeck Foundation Professor grant (R310-2018-3711)
Article History
Received: 25 April 2023
Accepted: 29 May 2023
First Online: 12 June 2023
Declarations
:
: The REFORM study received approval from both the Danish Data Protection Agency and the ethics committee of the Capital Region of Denmark (H-20033264 and H-20047793). All participants were given appropriate time to consider participation and provided written informed consent before undergoing any study-related procedures.
: Not applicable.
: WKK, CKC, HMA, and RHC declare no competing interests. HA reports receiving personal fees from Teva outside of the submitted work. FMA reports receiving personal fees from AbbVie, Pfizer, Teva, Lundbeck, Novartis, and Eli Lilly outside of the submitted work. FMA serves as an associate editor of Frontiers in Neurology, Frontiers in Pain Research, Headache Medicine and Acta Neurologica Scandinavica, and as junior associate editor of Cephalalgia. MA reports receiving personal fees from AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva Pharmaceuticals outside of the submitted work. MA also serves as an associate editor of Cephalalgia, The Journal of Headache and Pain, and Brain.